200 related articles for article (PubMed ID: 26877784)
1. Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.
Sörensen J; Velikyan I; Sandberg D; Wennborg A; Feldwisch J; Tolmachev V; Orlova A; Sandström M; Lubberink M; Olofsson H; Carlsson J; Lindman H
Theranostics; 2016; 6(2):262-71. PubMed ID: 26877784
[TBL] [Abstract][Full Text] [Related]
2. Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [
Altena R; Burén SA; Blomgren A; Karlsson E; Tzortzakakis A; Brun N; Moein MM; Jussing E; Frejd FY; Bergh J; Tran TA; Hartman J; Axelsson R
J Nucl Med; 2024 May; 65(5):700-707. PubMed ID: 38548353
[TBL] [Abstract][Full Text] [Related]
3. [
Lu Y; Li M; Massicano AVF; Song PN; Mansur A; Heinzman KA; Larimer BM; Lapi SE; Sorace AG
Molecules; 2021 Mar; 26(6):. PubMed ID: 33809310
[TBL] [Abstract][Full Text] [Related]
4. Good manufacturing practice production of [(68)Ga]Ga-ABY-025 for HER2 specific breast cancer imaging.
Velikyan I; Wennborg A; Feldwisch J; Lindman H; Carlsson J; Sörensen J
Am J Nucl Med Mol Imaging; 2016; 6(2):135-53. PubMed ID: 27186441
[TBL] [Abstract][Full Text] [Related]
5. Targeting HER2 in Nuclear Medicine for Imaging and Therapy.
Massicano AVF; Marquez-Nostra BV; Lapi SE
Mol Imaging; 2018; 17():1536012117745386. PubMed ID: 29357745
[TBL] [Abstract][Full Text] [Related]
6. Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.
Henry KE; Ulaner GA; Lewis JS
PET Clin; 2018 Jul; 13(3):423-435. PubMed ID: 30100080
[TBL] [Abstract][Full Text] [Related]
7. A Gallium-68-Labeled Peptide Radiotracer For CD38-Targeted Imaging In Multiple Myeloma With PET.
Sharma AK; Gupta K; Mishra A; Lofland G; Marsh I; Kumar D; Ghiaur G; Imus P; Hobbs RF; Gocke CB; Nimmagadda S
bioRxiv; 2023 Oct; ():. PubMed ID: 37214794
[TBL] [Abstract][Full Text] [Related]
8. Editorial Comment: Utilization of Radiomics to Identify HER2-Low Breast Cancer.
Panigrahi B
AJR Am J Roentgenol; 2024 Apr; 222(4):e2430953. PubMed ID: 38353453
[No Abstract] [Full Text] [Related]
9. Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy.
Eissler N; Altena R; Alhuseinalkhudhur A; Bragina O; Feldwisch J; Wuerth G; Loftenius A; Brun N; Axelsson R; Tolmachev V; Sörensen J; Frejd FY
Biomedicines; 2024 May; 12(5):. PubMed ID: 38791050
[TBL] [Abstract][Full Text] [Related]
10. Comparison of approaches for increasing affinity of affibody molecules for imaging of B7-H3: dimerization and affinity maturation.
Oroujeni M; Carlqvist M; Ryer E; Orlova A; Tolmachev V; Frejd FY
EJNMMI Radiopharm Chem; 2024 Apr; 9(1):30. PubMed ID: 38625607
[TBL] [Abstract][Full Text] [Related]
11. Molecular probes targeting HER2 PET/CT and their application in advanced breast cancer.
Gao F; Liu F; Wang J; Bi J; Zhai L; Li D
J Cancer Res Clin Oncol; 2024 Mar; 150(3):118. PubMed ID: 38466436
[TBL] [Abstract][Full Text] [Related]
12. Detection of HER2 expression using
Zhao L; Xing Y; Liu C; Ma S; Huang W; Cheng Z; Zhao J
Breast Cancer Res; 2024 Mar; 26(1):40. PubMed ID: 38459598
[TBL] [Abstract][Full Text] [Related]
13. Phase II Trial Assessing the Repeatability and Tumor Uptake of [
Gondry O; Caveliers V; Xavier C; Raes L; Vanhoeij M; Verfaillie G; Fontaine C; Glorieus K; De Grève J; Joris S; Luyten I; Zwaenepoel K; Vandenbroucke F; Waelput W; Thyparambil S; Vaneycken I; Cousaert J; Bourgeois S; Devoogdt N; Goethals L; Everaert H; De Geeter F; Lahoutte T; Keyaerts M
J Nucl Med; 2024 Feb; 65(2):178-184. PubMed ID: 38302159
[TBL] [Abstract][Full Text] [Related]
14. First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [
Zhang M; Kang F; Xing T; Wang J; Ma T; Li G; Quan Z; Yang W; Chen X; Wang J
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1713-1724. PubMed ID: 38216779
[TBL] [Abstract][Full Text] [Related]
15. Reduction of renal activity retention of radiolabeled albumin binding domain‑derived affinity proteins using a non‑residualizing label strategy compared with a cleavable glycine‑leucine‑glycine‑lysine‑linker.
Lundmark F; Vorobyeva A; Liu Y; Lindbo S; Xu T; Oroujeni M; Rinne SS; Rosenström U; Garousi J
Mol Med Rep; 2024 Feb; 29(2):. PubMed ID: 38186305
[TBL] [Abstract][Full Text] [Related]
16. ImmunoPET Targeting Receptor Tyrosine Kinase: Clinical Applications.
Linguanti F; Abenavoli EM; Calabretta R; Berti V; Lopci E
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136430
[TBL] [Abstract][Full Text] [Related]
17. Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [
Jussing E; Ferrat M; Moein MM; Alfredéen H; Tegnebratt T; Bratteby K; Samén E; Feldwisch J; Altena R; Axelsson R; Tran TA
EJNMMI Radiopharm Chem; 2023 Nov; 8(1):41. PubMed ID: 37991639
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical evaluation of
Bragina O; Chernov V; Larkina M; Rybina A; Zelchan R; Garbukov E; Oroujeni M; Loftenius A; Orlova A; Sörensen J; Frejd FY; Tolmachev V
Theranostics; 2023; 13(14):4858-4871. PubMed ID: 37771776
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
